Wells Fargo Initiates Coverage on Metsera (MTSR) with Optimistic Outlook | MTSR Stock News

Author's Avatar
Jun 20, 2025

Wells Fargo has begun covering Metsera (MTSR, Financial) with an Overweight rating, setting a price target of $65. The company is noted for its unique position in the competitive obesity market, offering treatments that require monthly dosing and maintain efficacy without adverse tolerance issues. According to Wells Fargo, investing in Metsera at current levels presents a strong risk/reward opportunity. The financial institution anticipates that upcoming data over the next year will further reinforce Metsera's distinctive market profile. Metsera's platform has successfully developed assets with substantial 18- and 19-day half-lives, showcasing its advanced capabilities in the field.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.